Abstract
It is known that the lipopolysaccharide (LPS) of gram-negative bacteria, in addition to being a potent adjuvant, is an effective carrier for covalently associated haptens. However, the toxic nature of most forms of LPS precludes their use as adjuvants or carriers for human vaccines. 4'-Monophosphoryl lipid A (MLA), a derivative of LPS with attenuated toxicity, is currently being tested in humans as an immunological adjuvant. In this study, MLA was tested for its ability to function as a carrier for a small hapten, the trinitrophenyl group (TNP). MLA was first modified by addition of 6-aminocaproic acid to the 6' position of the disaccharide backbone (Cap-MLA). TNP was then attached to Cap-MLA via the free amino group, yielding TNP-Cap-MLA. Immunization of normal mice with TNP-Cap-MLA resulted in high-titer anti-TNP responses of immunoglobulin M and all immunoglobulin G subclasses. Furthermore MLA, like other T-cell-independent type 1 (TI-1) carriers, induced responses in athymic and X-linked immunodeficient mice. In all cases, immunization with either MLA alone or TNP-Cap plus MLA failed to induce measurable anti-TNP antibodies of any isotype, indicating that covalent association of MLA and hapten was necessary for MLA's carrier activity to be manifested. These properties of MLA make it a potential candidate as a carrier for vaccine subunit components, such as small peptides, especially for situations in which T-cell help is impaired, as occurs following human immunodeficiency virus type 1 infection.
Full Text
The Full Text of this article is available as a PDF (353.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Altman A., Dixon F. J. Immunomodifiers in vaccines. Adv Vet Sci Comp Med. 1989;33:301–343. doi: 10.1016/b978-0-12-039233-9.50013-5. [DOI] [PubMed] [Google Scholar]
- BARTLETT G. R. Phosphorus assay in column chromatography. J Biol Chem. 1959 Mar;234(3):466–468. [PubMed] [Google Scholar]
- Bessler W. G., Jung G. Synthetic lipopeptides as novel adjuvants. Res Immunol. 1992 Jun;143(5):548–580. doi: 10.1016/0923-2494(92)80067-u. [DOI] [PubMed] [Google Scholar]
- Betts M., Beining P., Brunswick M., Inman J., Angus R. D., Hoffman T., Golding B. Lipopolysaccharide from Brucella abortus behaves as a T-cell-independent type 1 carrier in murine antigen-specific antibody responses. Infect Immun. 1993 May;61(5):1722–1729. doi: 10.1128/iai.61.5.1722-1729.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Carelli C., Ralamboranto L., Audibert F., Gaillard J., Briquelet N., Dray F., Fafeur V., Haour F., Chedid L. Immunological castration by a totally synthetic vaccine: modification of biological properties of LH-RH after conjugation to adjuvant-active muramyl peptide. Int J Immunopharmacol. 1985;7(2):215–224. doi: 10.1016/0192-0561(85)90029-3. [DOI] [PubMed] [Google Scholar]
- Cockfield S. M., Ramassar V., Halloran P. F. Regulation of IFN-gamma and tumor necrosis factor-alpha expression in vivo. Effects of cycloheximide and cyclosporine in normal and lipopolysaccharide-treated mice. J Immunol. 1993 Jan 15;150(2):342–352. [PubMed] [Google Scholar]
- Finkelman F. D., Holmes J., Katona I. M., Urban J. F., Jr, Beckmann M. P., Park L. S., Schooley K. A., Coffman R. L., Mosmann T. R., Paul W. E. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol. 1990;8:303–333. doi: 10.1146/annurev.iy.08.040190.001511. [DOI] [PubMed] [Google Scholar]
- Fries L. F., Gordon D. M., Richards R. L., Egan J. E., Hollingdale M. R., Gross M., Silverman C., Alving C. R. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):358–362. doi: 10.1073/pnas.89.1.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Golding H., Rittenberg M. B. In vivo allogeneic effects: shift in the isotype profile of primary TI-2 responses in mice undergoing graft-vs-host reaction. J Immunol. 1982 Nov;129(5):1878–1882. [PubMed] [Google Scholar]
- Goldstein J., Hoffman T., Frasch C., Lizzio E. F., Beining P. R., Hochstein D., Lee Y. L., Angus R. D., Golding B. Lipopolysaccharide (LPS) from Brucella abortus is less toxic than that from Escherichia coli, suggesting the possible use of B. abortus or LPS from B. abortus as a carrier in vaccines. Infect Immun. 1992 Apr;60(4):1385–1389. doi: 10.1128/iai.60.4.1385-1389.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Good M. F., Maloy W. L., Lunde M. N., Margalit H., Cornette J. L., Smith G. L., Moss B., Miller L. H., Berzofsky J. A. Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. Science. 1987 Feb 27;235(4792):1059–1062. doi: 10.1126/science.2434994. [DOI] [PubMed] [Google Scholar]
- Gustafson G. L., Rhodes M. J. A rationale for the prophylactic use of monophosphoryl lipid A in sepsis and septic shock. Biochem Biophys Res Commun. 1992 Jan 15;182(1):269–275. doi: 10.1016/s0006-291x(05)80140-8. [DOI] [PubMed] [Google Scholar]
- Gustafson G. L., Rhodes M. J. Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res Immunol. 1992 Jun;143(5):483–574. doi: 10.1016/0923-2494(92)80058-s. [DOI] [PubMed] [Google Scholar]
- Heath A. W., Playfair J. H. Conjugation of interferon-gamma to antigen enhances its adjuvanticity. Immunology. 1990 Nov;71(3):454–456. [PMC free article] [PubMed] [Google Scholar]
- Inman J. K., Merchant B., Claflin L., Tacey S. E. Coupling of large haptens to proteins and cell surfaces: preparation of stable, optimally sensitized erythrocytes for hapten-specific, hemolytic plaque assays. Immunochemistry. 1973 Mar;10(3):165–174. doi: 10.1016/0019-2791(73)90005-0. [DOI] [PubMed] [Google Scholar]
- Inman J. K., Merchant B., Tacey S. E. Synthesis of large haptenic compounds having a common functional group that permits covalent linkage to proteins, cell surfaces, and adsorbents. Immunochemistry. 1973 Mar;10(3):153–163. doi: 10.1016/0019-2791(73)90004-9. [DOI] [PubMed] [Google Scholar]
- Inman J. K. Thymus-independent antigens: the preparation of covalent, hapten-ficoll conjugates. J Immunol. 1975 Feb;114(2 Pt 1):704–709. [PubMed] [Google Scholar]
- JOHNSON A. G., GAINES S., LANDY M. Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide. J Exp Med. 1956 Feb 1;103(2):225–246. doi: 10.1084/jem.103.2.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mitchell M. S., Kan-Mitchell J., Kempf R. A., Harel W., Shau H. Y., Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 1988 Oct 15;48(20):5883–5893. [PubMed] [Google Scholar]
- Myers K. R., Ulrich J. T., Qureshi N., Takayama K., Wang R., Chen L., Emary W. B., Cotter R. J. Preparation and characterization of biologically active 6'-O-(6-aminocaproyl)-4'-O-monophosphoryl lipid A and its conjugated derivative. Bioconjug Chem. 1992 Nov-Dec;3(6):540–548. doi: 10.1021/bc00018a013. [DOI] [PubMed] [Google Scholar]
- Phillips M., Pugh G. W., Jr, Deyoe B. L. Chemical and protective properties of Brucella lipopolysaccharide obtained by butanol extraction. Am J Vet Res. 1989 Mar;50(3):311–317. [PubMed] [Google Scholar]
- Rao K. V., Nayak A. R. Enhanced immunogenicity of a sequence derived from hepatitis B virus surface antigen in a composite peptide that includes the immunostimulatory region from human interleukin 1. Proc Natl Acad Sci U S A. 1990 Jul;87(14):5519–5522. doi: 10.1073/pnas.87.14.5519. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rickman L. S., Gordon D. M., Wistar R., Jr, Krzych U., Gross M., Hollingdale M. R., Egan J. E., Chulay J. D., Hoffman S. L. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet. 1991 Apr 27;337(8748):998–1001. doi: 10.1016/0140-6736(91)92659-p. [DOI] [PubMed] [Google Scholar]
- Rittenberg M. B., Amkraut A. A. Immunogenicity of trinitrophenyl-hemocyanin: production of primary and secondary anti-hapten precipitins. J Immunol. 1966 Sep;97(3):421–430. [PubMed] [Google Scholar]
- Rudbach J. A., Myers K. R., Rechtman D. J., Ulrich J. T. Prophylactic use of monophosphoryl lipid A in patients at risk for sepsis. Prog Clin Biol Res. 1994;388:107–124. [PubMed] [Google Scholar]
- Schenck J. R., Hargie M. P., Brown M. S., Ebert D. S., Yoo A. L., McIntire F. C. The enhancement of antibody formation by Escherichia coli lipopolysaccharide and detoxified derivatives. J Immunol. 1969 Jun;102(6):1411–1422. [PubMed] [Google Scholar]
- Scher I. CBA/N immune defective mice; evidence for the failure of a B cell subpopulation to be expressed. Immunol Rev. 1982;64:117–136. doi: 10.1111/j.1600-065x.1982.tb00421.x. [DOI] [PubMed] [Google Scholar]
- Skea D. L., Barber B. H. Adjuvant-independent induction of immune responses by antibody-mediated targeting of protein and peptide antigens. Res Immunol. 1992 Jun;143(5):568–572. doi: 10.1016/0923-2494(92)80071-r. [DOI] [PubMed] [Google Scholar]
- Slack J., Der-Balian G. P., Nahm M., Davie J. M. Subclass restriction of murine antibodies. II. The IgG plaque-forming cell response to thymus-independent type 1 and type 2 antigens in normal mice and mice expressing an X-linked immunodeficiency. J Exp Med. 1980 Apr 1;151(4):853–862. doi: 10.1084/jem.151.4.853. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Takayama K., Qureshi N., Ribi E., Cantrell J. L. Separation and characterization of toxic and nontoxic forms of lipid A. Rev Infect Dis. 1984 Jul-Aug;6(4):439–443. doi: 10.1093/clinids/6.4.439. [DOI] [PubMed] [Google Scholar]
- Vosika G. J., Barr C., Gilbertson D. Phase-I study of intravenous modified lipid A. Cancer Immunol Immunother. 1984;18(2):107–112. doi: 10.1007/BF00205743. [DOI] [PMC free article] [PubMed] [Google Scholar]